Geode Capital Management, LLC Tiziana Life Sciences LTD Transaction History

Geode Capital Management, LLC

  • $1.12 Trillion
  • Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Tiziana Life Sciences LTD stock. As of the latest transaction made, Geode Capital Management, LLC holds 219,521 shares of TLSA stock, worth $226,106. This represents 0.0% of its overall portfolio holdings.

Number of Shares
219,521
Previous 215,825 1.71%
Holding current value
$226,106
Previous $97,000 107.22%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024
BUY
$0.43 - $1.01 $1,589 - $3,732
3,696 Added 1.71%
219,521 $201,000
Q1 2024

May 13, 2024
BUY
$0.42 - $0.61 $1,956 - $2,841
4,658 Added 2.21%
215,825 $97,000
Q4 2023

Feb 13, 2024
BUY
$0.55 - $0.85 $2,613 - $4,038
4,751 Added 2.3%
211,167 $118,000
Q3 2023

Nov 13, 2023
BUY
$0.6 - $0.82 $2,671 - $3,651
4,453 Added 2.2%
206,416 $136,000
Q2 2023

Aug 11, 2023
BUY
$0.65 - $1.29 $975 - $1,936
1,501 Added 0.75%
201,963 $137,000
Q1 2023

May 15, 2023
BUY
$0.51 - $1.1 $1,772 - $3,823
3,476 Added 1.76%
200,462 $218,000
Q4 2022

Feb 13, 2023
BUY
$0.56 - $0.78 $1,327 - $1,848
2,370 Added 1.22%
196,986 $119,000
Q3 2022

Nov 14, 2022
BUY
$0.55 - $0.83 $3,519 - $5,311
6,399 Added 3.4%
194,616 $151,000
Q2 2022

Aug 12, 2022
BUY
$0.66 - $1.06 $1,668 - $2,679
2,528 Added 1.36%
188,217 $140,000
Q1 2022

May 13, 2022
BUY
$0.62 - $1.25 $27,154 - $54,746
43,797 Added 30.87%
185,689 $194,000
Q4 2021

Feb 11, 2022
BUY
$0.89 - $1.66 $126,283 - $235,540
141,892 New
141,892 $136,000

Others Institutions Holding TLSA

# of Institutions
27
Shares Held
929K
Call Options Held
0
Put Options Held
0
View Full List

About Tiziana Life Sciences Ltd

TLSA Quotes by TradingView
  • Ticker TLSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,273,000
  • Market Cap $105M
  • Description
  • Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...
More about TLSA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email